Connect Biopharma to Participate at Upcoming Conferences
November 11 2021 - 8:00AM
Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect
Biopharma” or the “Company”), a global clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients with chronic inflammatory diseases through the development
of therapies derived from T cell-driven research, today announced
that Dr. Zheng Wei, Co-Founder & CEO, and Dr. Selwyn Ho, Chief
Business Officer, will be participating in fireside chats at the
following conferences:
- Jefferies London Healthcare
ConferenceThe fireside chat will be available to view
on-demand beginning Thursday, November 18 at 8:00 a.m. GMT / 3:00
a.m. ET.
-
33rd Annual Piper Sandler
Healthcare ConferenceThe fireside chat will be available
to view on-demand beginning Monday, November 22 at 10:00 a.m.
ET.
Webcasts of both fireside chats will be
available on the Company’s Investor Relations page accessible here:
https://investors.connectbiopharm.com/. Replays will be available
on the Company’s website following the event.
About Connect Biopharma Holdings
LimitedConnect Biopharma Holdings Limited is a global
clinical-stage biopharmaceutical company dedicated to improving the
lives of patients living with chronic inflammatory diseases through
the development of therapies derived from our T cell-driven
research.
Our lead product candidate, CBP-201, an antibody
designed to target interleukin-4 receptor alpha (IL-4Rα), has been
in clinical trials for the treatment of atopic dermatitis (AD),
asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP). Our
second lead product candidate, CBP-307, a modulator of a T cell
receptor known as sphingosine 1-phosphate receptor 1 (S1P1), has
been in clinical trials for the treatment of ulcerative colitis
(UC) and Crohn’s disease (CD). Furthermore, we have started the
clinical development of an additional product candidate, CBP-174, a
peripherally acting antagonist of histamine receptor 3, for the
treatment of pruritus associated with AD.
With headquarters in China, additional
operations in the United States and Australia, and clinical
development activities in those geographies as well as Europe,
Connect Biopharma is building a rich global pipeline of internally
designed, wholly owned small molecules and antibodies targeting
several aspects of T cell biology. For additional information about
Connect Biopharma, please visit our website at
www.connectbiopharm.com.
IR/PR CONTACTS: Lazar FINN Partners David
Carey (IR) T: +1-(212)
867-1768david.carey@finnpartners.comErich Sandoval
(Media) +1-(646) 871-8482 or +1-(917)
497-2867erich.sandoval@finnpartners.com
Corporate
Contacts:info@connectpharm.com
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Apr 2023 to Apr 2024